MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.204
NaN%
Closed 09:30 04/02 EDT
OPEN
--
PREV CLOSE
0.189
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.288
52 WEEK LOW
0.134
MARKET CAP
24.56M
P/E (TTM)
-6.2195
1D
5D
1M
3M
1Y
5Y
1D
Diagnos completes annual US FDA medical device facility registration renewal
Reuters · 3d ago
Diagnos extends expiry of 5.23 million warrants to Sept. 25, 2026
Reuters · 3d ago
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
Barchart · 3d ago
Diagnos Extends Expiry of 8,333,333 Stock Warrants to Sept. 5, 2026
Reuters · 03/05 21:06
Diagnos Extends Convertible Debenture Maturity to March 2027 and Cuts Conversion Price to $0.32
Reuters · 03/05 20:45
DIAGNOS ANNOUNCES AMENDMENTS TO CONVERTIBLE DEBENTURES AND STOCK WARRANTS
Reuters · 03/05 20:45
Diagnos posts 9M net loss of CAD 3.4 million
Reuters · 02/25 17:50
Diagnos Inc. Publishes MD&A for Three-Month and Nine-Month Periods Ended Dec. 31, 2025
Reuters · 02/25 17:49
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.